These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 22075285)

  • 21. Terlipressin in hepatorenal syndrome: Evidence for present indications.
    Rajekar H; Chawla Y
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.
    Testro AG; Wongseelashote S; Angus PW; Gow PJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1535-40. PubMed ID: 17784863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.
    Krag A; Møller S; Henriksen JH; Holstein-Rathlou NH; Larsen FS; Bendtsen F
    Hepatology; 2007 Dec; 46(6):1863-71. PubMed ID: 18027874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
    Sagi SV; Mittal S; Kasturi KS; Sood GK
    J Gastroenterol Hepatol; 2010 May; 25(5):880-5. PubMed ID: 20074149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.
    Rodríguez E; Elia C; Solà E; Barreto R; Graupera I; Andrealli A; Pereira G; Poca M; Sánchez J; Guevara M; Soriano G; Alessandria C; Fernández J; Arroyo V; Ginès P
    J Hepatol; 2014 May; 60(5):955-61. PubMed ID: 24447876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
    Singh V; Dhungana SP; Singh B; Vijayverghia R; Nain CK; Sharma N; Bhalla A; Gupta PK
    J Hepatol; 2012 Feb; 56(2):348-54. PubMed ID: 21749847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
    Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation.
    Caraceni P; Santi L; Mirici F; Montanari G; Bevilacqua V; Pinna AD; Bernardi M
    Dig Liver Dis; 2011 Mar; 43(3):242-5. PubMed ID: 20833118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis.
    Krag A; Bendtsen F; Mortensen C; Henriksen JH; Møller S
    Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1085-92. PubMed ID: 20453655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.
    Mulkay JP; Louis H; Donckier V; Bourgeois N; Adler M; Deviere J; Le Moine O
    Acta Gastroenterol Belg; 2001; 64(1):15-9. PubMed ID: 11322061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.
    Narahara Y; Kanazawa H; Sakamoto C; Maruyama H; Yokosuka O; Mochida S; Uemura M; Fukui H; Sumino Y; Matsuzaki Y; Masaki N; Kokubu S; Okita K
    J Gastroenterol; 2012 Mar; 47(3):313-20. PubMed ID: 22038555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hepatorenal syndrome: diagnosis, treatment and prevention].
    Egerod Israelsen M; Gluud LL; Bendtsen F; Møller S; Krag AA
    Ugeskr Laeger; 2013 May; 175(22):1562-6. PubMed ID: 23721840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review article: pharmacological treatment of hepatorenal syndrome.
    Ginès P; Torre A; Terra C; Guevara M
    Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():57-62; discussion 63-4. PubMed ID: 15335404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.
    Alessandria C; Debernardi-Venon W; Carello M; Ceretto S; Rizzetto M; Marzano A
    Dig Liver Dis; 2009 Apr; 41(4):298-302. PubMed ID: 19158001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis.
    Narahara Y; Kanazawa H; Taki Y; Kimura Y; Atsukawa M; Katakura T; Kidokoro H; Harimoto H; Fukuda T; Matsushita Y; Nakatsuka K; Sakamoto C
    J Gastroenterol Hepatol; 2009 Nov; 24(11):1791-7. PubMed ID: 19686420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Observation of the therapeutic and characteristic effects of terlipressin on refractory cirrhotic ascites].
    Xing F; Li S; Zhang JJ; Sun CY; Huang JR; Gao ZL; Zhu TT; Zhao Q; Zhang H; Liu CH
    Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):982-988. PubMed ID: 31941260
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study.
    Moreau R; Asselah T; Condat B; de Kerguenec C; Pessione F; Bernard B; Poynard T; Binn M; Grangé JD; Valla D; Lebrec D
    Gut; 2002 Jan; 50(1):90-4. PubMed ID: 11772973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
    Ghosh S; Choudhary NS; Sharma AK; Singh B; Kumar P; Agarwal R; Sharma N; Bhalla A; Chawla YK; Singh V
    Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
    Colle I; Durand F; Pessione F; Rassiat E; Bernuau J; Barrière E; Lebrec D; Valla DC; Moreau R
    J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?
    Piano S; Morando F; Fasolato S; Cavallin M; Boscato N; Boccagni P; Zanus G; Cillo U; Gatta A; Angeli P
    J Hepatol; 2011 Aug; 55(2):491-6. PubMed ID: 21334405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.